Featured Research

from universities, journals, and other organizations

Mayo Clinic First To Use Pharmacogenomics To Treat Inherited Kidney Disorder Of Children

Date:
May 6, 2005
Source:
Mayo Clinic
Summary:
Mayo Clinic researchers have used pharmacogenomics to develop a test and treatment for an inherited kidney disorder that can cause organ failure in children and young adults. The findings appear in the current issue of the journal Kidney International. Pharmacogenomics tailors treatment to an individual's genetic makeup to maximize the therapeutic response.

Mayo Clinic researchers have used pharmacogenomics to develop a test and treatment for an inherited kidney disorder that can cause organ failure in children and young adults. The findings appear in the current issue of the journal Kidney International. Pharmacogenomics tailors treatment to an individual's genetic makeup to maximize the therapeutic response.

Related Articles


Early diagnosis is important, as the condition -- type I primary hyperoxaluria -- if not treated early and correctly, can cause kidney stones or kidney failure and necessitate a transplant. The researchers discovered that a genetic mutation allows certain kidney stone patients -- many of them children -- to benefit from vitamin B6, and have used the finding to develop a genetic test to predict which patients are best suited for this treatment.

In discovering the link between a specific mutation and vitamin B6 responsiveness, the Mayo Clinic researchers can now use a genetic test for guiding treatment to maximize the probability of swift, successful treatment for select cases of type I primary hyperoxaluria. The disease is uncommon, but if left undiagnosed and untreated, at least half of those affected will suffer kidney failure. Patients most often develop the first symptoms -- usually kidney stones -- during infancy or childhood. However, the disorder may go unrecognized until age 30 to 40. In some cases the first symptom is kidney failure.

The gene defect responsible for the disorder disrupts production of a key enzyme located in the liver, and this enzymatic deficit then allows the liver to produce too much oxalate, which is excreted in the urine. High concentrations of oxalate in the urine can cause kidney stones and injury to the kidney, leading to kidney failure.

"While there are still questions to resolve -- such as determining the most effective dose, and the safety of vitamin B6 if very high doses are used -- our demonstration of the relationship between a specific mutation and vitamin B6 responsiveness does open the door to informed use of this valuable agent in the treatment of type I primary hyperoxaluria," says Carla Monico, M.D., Mayo Clinic nephrologist and lead researcher on the study. The research team will now try to determine the most effective doses and evaluate benefits of this approach long term.

The Problem and the Mayo solution

Doctors have known for more than 40 years that vitamin B6 therapy can effectively lower the dangerous oxalate levels in urine of patients with type I primary hyperoxaluria. But the clinical usefulness of that information has been limited by the fact that vitamin B6's therapeutic effect only occurs in about 50 percent of patients. No one knew why.

Mayo Clinic researchers now have both an explanation for the varied response and a way to predict who will respond to vitamin B6 therapy. By studying 23 patients' genetic profiles and their response rates to various dose levels of vitamin B6, the researchers found that a specific gene mutation governs how a patient will respond to vitamin B6. As a result, researchers can now use a genetic test to identify patients best suited for this therapy.

Collaboration and Support

In addition to Dr. Monico, other members of the Mayo Clinic research team included Sandro Rossetti, M.D.; Julie Olson; and Dawn Milliner, M.D. Their work was supported by grants from the National Institutes of Health and the Oxalosis and Hyperoxaluria Foundation.


Story Source:

The above story is based on materials provided by Mayo Clinic. Note: Materials may be edited for content and length.


Cite This Page:

Mayo Clinic. "Mayo Clinic First To Use Pharmacogenomics To Treat Inherited Kidney Disorder Of Children." ScienceDaily. ScienceDaily, 6 May 2005. <www.sciencedaily.com/releases/2005/05/050505223749.htm>.
Mayo Clinic. (2005, May 6). Mayo Clinic First To Use Pharmacogenomics To Treat Inherited Kidney Disorder Of Children. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2005/05/050505223749.htm
Mayo Clinic. "Mayo Clinic First To Use Pharmacogenomics To Treat Inherited Kidney Disorder Of Children." ScienceDaily. www.sciencedaily.com/releases/2005/05/050505223749.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins